TECENTRIQ DIN 02462990
Status: Marketed
Holder: HOFFMANN-LA ROCHE LIMITED
Available to quote
Health Canada record
| Active ingredient(s) | ATEZOLIZUMAB 1200 MG |
|---|
| Dosage form | Solution |
|---|
| Route | Intravenous |
|---|
| Schedule | SCHEDULE D; PRESCRIPTION |
|---|
| Class | Human |
|---|
| ATC | L01FF05 ATEZOLIZUMAB |
|---|
| Original market date | 02-May-2017 |
|---|
| Current status date | 02-May-2017 |
|---|
| Source | Health Canada DPD |
|---|
Establishment licence of the holder
Hoffmann-La Roche Limited — licence 100006, currently licensed, last inspection rating C (2024-06-25).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing ATEZOLIZUMAB
| DIN | Product | Company | Form | Strength | Status |
|---|
| 02492393 | TECENTRIQ | HOFFMANN-LA ROCHE LIMITED | Solution | ATEZOLIZUMAB 840 MG | Marketed |
| 02546310 | TECENTRIQ SC | HOFFMANN-LA ROCHE LIMITED | Solution | ATEZOLIZUMAB 125 MG | Marketed |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|
| 19156 | 2017-04-12 | New Drug Submission (NDS) | |
Request a quote for TECENTRIQ
How to read a Canadian DIN record